# Migraine:  Developing Drugs for Preventive Treatment - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/migraine-developing-drugs-for-preventive-treatment/cd739d7c-f8ed-4a37-b16f-d6f3b9550a94

> FDA guidance document: Migraine:  Developing Drugs for Preventive Treatment. Issue date: June 01, 2023. Get complete insights and analysis.

---

## Details

- Title: Migraine:  Developing Drugs for Preventive Treatment
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2023-06-01
- Comment Close Date: 2023-08-01
- Last Changed: 2023-06-01
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2022-D-1729">FDA-2022-D-1729</a>

## Related Documents

- [Stimulant Use Disorders: Developing Drugs for Treatment](https://www.globalkeysolutions.net/guidances/guidance-document/stimulant-use-disorders-developing-drugs-for-treatment/396da81b-e089-444c-9781-b40a43a1cff2)
- [Endogenous Cushing’s Syndrome: Developing Drugs for Treatment](https://www.globalkeysolutions.net/guidances/guidance-document/endogenous-cushings-syndrome-developing-drugs-for-treatment/c89a914f-8df3-4543-87dc-697dcbc10611)
- [Nonalcoholic Steatohepatitis with Compensated Cirrhosis: Developing Drugs for Treatment Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/nonalcoholic-steatohepatitis-with-compensated-cirrhosis-developing-drugs-for-treatment-guidance-for-industry/71c114f5-4930-4cda-87ef-12936678931f)